5-Amino-4-oxopentanoic acid |
| カタログ番号GC32608 |
5-アミノ-4-オキソペンタン酸 (5-ALA) は、ヘム生合成において律速の役割を果たす非タンパク質アミノ酸です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 106-60-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5-Amino-4-oxopentanoic acid is a naturally occurring non-proteinogenic amino acid and a prodrug of the photosensitizer protoporphyrin IX (PpIX). 5-Amino-4-oxopentanoic acid can be activated by laser light at a wavelength of about 635nm (580 to 740nm) to emit red fluorescence (620 to 710nm), and can be used as a photodiagnostic agent for a variety of cancers[1-4].
5-Amino-4-oxopentanoic acid can inhibit the viability of U87MG cells with an IC50 of 500μg/mL. 5-Amino-4-oxopentanoic acid (250μg/mL) can induce apoptosis of U87MG cells, promote the expression of Bax and p53, and inhibit the expression of Bcl-2. 5-Amino-4-oxopentanoic acid increased the accumulation of U87MG cells in the SUB-G1 population, reduced the expression of cyclin D1, and reduced the migration ability of U87MG cells[2]. When using photodynamic therapy, HCC cells were treated with different concentrations (0-0.6mM) of 5-Amino-4-oxopentanoic acid at different illumination doses (0-3.6J/cm2). 5-Amino-4-oxopentanoic acid inhibited the viability of HCC cells in a dose-dependent manner[3].
5-Amino-4-oxopentanoic acid (200mg/kg)-mediated photodynamic therapy can inhibit the growth rate of mouse tumors in the SCID mouse hepatocellular carcinoma model[3]. 5-Amino-4-oxopentanoic acid (30 or 300mg/kg/day) can promote caspase 3-dependent apoptosis in the carcinogenesis of transgenic prostate adenocarcinoma (FVB-TRAMP) mice by supporting the functional expression of mitochondrial cytochrome c and cytochrome c oxidase subunit 4 (COX4), thereby reducing the tumor burden in mice[4].
References:
[1] Pignatelli P, Umme S, D’Antonio D L, et al. Reactive oxygen species produced by 5-aminolevulinic acid photodynamic therapy in the treatment of cancer[J]. International Journal of Molecular Sciences, 2023, 24(10): 8964.
[2] Jalili-Nik M, Abbasinezhad-Moud F, Sahab-Negah S, et al. Antitumor effects of 5-Aminolevulinic acid on human malignant glioblastoma cells[J]. International Journal of Molecular Sciences, 2021, 22(11): 5596.
[3] Kumar A, Pecquenard F, Baydoun M, et al. An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma[J]. International Journal of Molecular Sciences, 2023, 24(13): 10426.
[4] Onishi K, Miyake M, Tatsumi Y, et al. Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model[J]. Asian Pacific Journal of Cancer Prevention: APJCP, 2020, 21(12): 3743.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *